Kari Braun Wisinski MD (She/Her)

Breast Cancer

Professor, Chief of Hematology/Oncology and Palliative Care. Deputy Director, Carbone Cancer Center. Leader of Breast cancer clinical trials and collaborative translational research.

Join to View Full Profile

600 Highland AveMadison, WI 53792
Phone+1 608-916-0500

Summary

Dr. Kari Wisinski is a professor and breast medical oncologist at the University of Wisconsin (UW) Carbone Cancer Center and Chief of the Division of Hematology, Medical Oncology and Palliative Care, UW School of Medicine and Public Health. She is experienced in clinical research and leads the UWCCC Breast Cancer Clinical Research team and is engaged in the BigTen Cancer Research Consortium.

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
University of ColoradoResidency, Internal Medicine, 2001 - 2004
Washington University in St. Louis School of MedicineClass of 2001

Certifications & Licensure

WI State Medical License 2008 - 2027
IL State Medical License 2005 - 2017
CO State Medical License 2003 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Interim Chief of Hematology, Medical Oncology and Palliative Care UW School of Medicine and Public Health, 2020
Vice chair, then Chair BigTen Cancer Research Consortium Steering Committee 2018-2020
Breast Disease Oriented Team Co-Leader UWCCC, 2017-2020
Head of Solid Tumor Oncology UW Division of Hematology, Medical Oncology and Palliative Care, 2015-2020
Join now to see all

Clinical Trials

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Start of enrollment: 2017 Feb 01
COMPLETED
PHASE2
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR Start of enrollment: 2017 May 03
Terminated
Phase 2
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Start of enrollment: 2016 Sep 02
COMPLETED
PHASE1
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer Start of enrollment: 2017 Nov 07
Completed
Phase 2
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer Start of enrollment: 2018 Dec 06
COMPLETED
PHASE2
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Start of enrollment: 2019 Apr 17
Active, not recruiting
Phase 1, Phase 2
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer Start of enrollment: 2021 Feb 12
RECRUITING
PHASE2
Roles: Sponsor-Investigator, Principal Investigator, Contact
Ribociclib and Bicalutamide in AR+ TNBC Start of enrollment: 2018 May 07
RECRUITING
PHASE1, PHASE2
Roles: Principal Investigator, Sponsor-Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft
Journal of the National Comprehensive Cancer Network. 2025-11-01
The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404).
Mamta Parikh, Nataliya V Uboha, Naoko Takebe, Kit Tam, Philippe L Bedard
Cancer Research Communications. 2025-11-01
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels.
Kyle T Helzer, Marina N Sharifi, Jamie M Sperger, Matthew R Chrostek, Matthew L Bootsma
Nature Communications. 2025-10-14

Lectures

Novel Approaches for HER2-Negative Metastatic Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

21 Oncology Leaders on the Innovations Transforming Breast Cancer CareOctober 29th, 2025
World Breast Cancer Research DayAugust 18th, 2025
Deferring CDK4/6 Inhibitor Treatment in HR-Positive/HER2-Negative Advanced BC May Not Impact HRQOLJanuary 7th, 2025
Join now to see all